Gilead Sciences Financials
| GILD Stock | USD 111.53 1.58 1.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 1.03 | 0.98 |
|
| |||||
| Current Ratio | 1.56 | 1.64 |
|
|
The financial analysis of Gilead Sciences is a critical element in measuring its lifeblood. Investors should not minimize Gilead Sciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Gilead | Select Account or Indicator |
Understanding current and past Gilead Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gilead Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Gilead Sciences' assets may result in an increase in income on the income statement.
Gilead Sciences Earnings Geography
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.
Gilead Sciences Stock Summary
Gilead Sciences competes with Amgen, Merck, AbbVie, Johnson Johnson, and Bristol Myers. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people.| Foreign Associate | Mexico |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US3755581036 |
| CUSIP | 375558103 |
| Location | California; U.S.A |
| Business Address | 333 Lakeside Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gilead.com |
| Phone | 650 574 3000 |
| Currency | USD - US Dollar |
Gilead Sciences Key Financial Ratios
| Return On Equity | 0.0229 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.33 % | ||||
| Price To Sales | 4.81 X | ||||
| Revenue | 28.75 B |
Gilead Sciences Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 68.4B | 68.0B | 63.2B | 62.1B | 71.4B | 75.0B | |
| Other Current Liab | 7.2B | 8.9B | 7.1B | 7.7B | 8.9B | 9.3B | |
| Net Debt | 25.4B | 21.4B | 19.8B | 18.9B | 21.7B | 22.8B | |
| Retained Earnings | 14.4B | 16.3B | 15.7B | 16.3B | 18.7B | 19.7B | |
| Accounts Payable | 844M | 705M | 905M | 550M | 632.5M | 518.2M | |
| Cash | 6.0B | 5.3B | 5.4B | 6.1B | 7.0B | 3.8B | |
| Other Current Assets | 2.0B | 2.1B | 1.8B | 2.4B | 2.7B | 2.9B | |
| Total Liab | 50.2B | 46.9B | 42.0B | 39.4B | 45.3B | 47.5B | |
| Total Current Assets | 15.8B | 15.1B | 15.2B | 16.1B | 18.5B | 10.8B | |
| Short Term Debt | 2.8B | 1.5B | 2.3B | 1.8B | 2.1B | 2.2B | |
| Net Receivables | 4.9B | 4.5B | 4.8B | 4.7B | 5.4B | 5.6B | |
| Inventory | 3.0B | 2.7B | 2.8B | 1.8B | 2.1B | 1.3B | |
| Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
| Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
| Long Term Debt | 28.6B | 25.2B | 23.0B | 23.2B | 26.7B | 28.0B | |
| Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
| Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Gilead Sciences Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 984M | 1.0B | 935M | 944M | 977M | 549.9M | |
| Total Revenue | 24.7B | 27.3B | 27.3B | 27.1B | 28.8B | 30.2B | |
| Gross Profit | 20.1B | 20.7B | 21.6B | 27.1B | 78.2M | 74.3M | |
| Operating Income | 7.0B | 7.4B | 7.3B | 7.6B | 1.7B | 1.6B | |
| Ebit | 2.7B | 9.3B | 6.7B | 7.6B | 8.7B | 4.5B | |
| Ebitda | 4.1B | 11.3B | 8.9B | 7.6B | 1.7B | 1.6B | |
| Cost Of Revenue | 4.6B | 6.6B | 5.7B | 5.8B | 28.7B | 30.1B | |
| Income Before Tax | 1.7B | 8.3B | 5.8B | 6.9B | 690M | 655.5M | |
| Net Income | 89M | 6.2B | 4.6B | 5.7B | 480M | 456M | |
| Income Tax Expense | 1.6B | 2.1B | 1.2B | (1.2B) | 211M | 200.5M | |
| Research Development | 5.0B | 5.4B | 5.0B | 5.7B | 5.9B | 6.2B | |
| Minority Interest | (34M) | 24M | 26M | 47M | 54.1M | 56.8M | |
| Tax Provision | 1.6B | 2.1B | 1.2B | 1.4B | 1.3B | 2.2B | |
| Net Interest Income | (984M) | (1.0B) | (935M) | (918M) | (1.1B) | (1.1B) |
Gilead Sciences Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (5.6B) | (659M) | 74M | 673M | 3.9B | 4.1B | |
| Free Cash Flow | 7.5B | 10.8B | 8.3B | 7.4B | 10.8B | 11.4B | |
| Depreciation | 1.5B | 2.1B | 2.1B | 2.7B | 3.1B | 3.3B | |
| Other Non Cash Items | 7.8B | 2.1B | 5.1B | 2.2B | 10.8B | 11.4B | |
| Capital Expenditures | 825M | 650M | 579M | 728M | 585M | 0.0 | |
| Net Income | 89M | 6.2B | 4.6B | 5.6B | 6.5B | 6.8B | |
| End Period Cash Flow | 6.0B | 5.3B | 5.4B | 6.1B | 10.0B | 10.5B | |
| Change To Inventory | (95M) | (195M) | 11M | (842M) | (757.8M) | (719.9M) | |
| Change To Netincome | (478M) | 6.5B | 11.4B | 3.5B | 4.0B | 4.2B | |
| Investments | 11.9B | (3.1B) | (2.5B) | (1.9B) | (2.2B) | (2.1B) | |
| Change Receivables | (218M) | (1.2B) | 313M | (406M) | (466.9M) | (490.2M) | |
| Net Borrowings | (2.8B) | 5.7B | (4.8B) | (1.5B) | (1.4B) | (1.3B) | |
| Dividends Paid | 3.4B | 3.6B | 3.7B | (3.8B) | (3.4B) | (3.3B) |
Gilead Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gilead Sciences competition to find correlations between indicators driving Gilead Sciences's intrinsic value. More Info.Gilead Sciences is rated below average in return on equity category among its peers. It is rated # 2 in return on asset category among its peers reporting about 4.90 of Return On Asset per Return On Equity. At present, Gilead Sciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Gilead Sciences Systematic Risk
Gilead Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gilead Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Gilead Sciences correlated with the market. If Beta is less than 0 Gilead Sciences generally moves in the opposite direction as compared to the market. If Gilead Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gilead Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gilead Sciences is generally in the same direction as the market. If Beta > 1 Gilead Sciences moves generally in the same direction as, but more than the movement of the benchmark.
Gilead Sciences Thematic Clasifications
Gilead Sciences is part of several thematic ideas from Macroaxis Index to Corona Opportunity. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Gilead Sciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gilead Sciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Gilead Sciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Gilead Sciences February 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Gilead Sciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gilead Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gilead Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Gilead Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gilead Sciences's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.55 | |||
| Information Ratio | 0.182 | |||
| Maximum Drawdown | 9.23 | |||
| Value At Risk | (2.04) | |||
| Potential Upside | 2.28 |
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |